Stock Analiz

SAB Biotherapeutics, Inc. (SABS) stock forecast and price target

Price $2.96 · data as of November 13, 2026

12-month price target

Average target$11.64
Upside / downside+293.1%
Analysts11
ConsensusStrong buy
Low $6.00Average $11.64High $16.00

Gold marker: average target · white marker: today’s price ($2.96)

Analyst ratings

Strong buy 1Buy 10Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-1.13−39.5%$0
Next fiscal year
ends December 31, 2027
$-0.94+16.3%$62500
Next quarter
ends December 31, 2026
$-0.24+40.6%$0
Quarter after
ends March 31, 2027
$-0.25—$0

Consensus of the analysts covering SAB Biotherapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.

Frequently asked questions

What is the SAB Biotherapeutics stock price target?

The average 12-month target from 11 analysts is $11.64, 293.1% above the current price of $2.96 Targets range from $6.00 to $16.00.

Is SAB Biotherapeutics a buy according to analysts?

The consensus rating is “Strong buy” (1 strong buy, 10 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is SAB Biotherapeutics expected to earn?

Analysts expect EPS of $-1.13 for the fiscal year ending December 31, 2026 and $-0.94 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.